Document is current

Any future updates will be listed below

Damaging non-synonymous mutations in the extracellular domain of HER2 potentially alter the efficacy of Herceptin-mediated breast cancer therapy

Crossref DOI link: https://doi.org/10.1186/s43042-025-00775-8

Published Online: 2025-09-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark